{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:41:54Z","timestamp":1791427314984,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006599","name":"Focused Ultrasound Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify MRI features of desmoid tumors (DTs) that predict the growth of residual disease following ablation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent MRI-guided ablation for DTs between February 2013 and April 2021 were included in this single-center IRB-approved retrospective study. MRI scans assessed three suspicious tissue features: intermediate T2 signal [+iT2], nodular appearance [+NOD], and contrast enhancement [+ENH]. Percent-monthly change in diameter (PMCD) of suspicious foci determined growth (PMCD\u2009&gt;\u20091%), unchanged (PMCD between \u22121% and +1%), or regression (PMCD\u2009&lt;\u2009\u22121%). Statistical tests compared mean PMCD between groups and evaluated sensitivity and specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-three patients (32 years\u2009\u00b1\u200913.3; 22 females) with 34 DTs underwent 47 MRI-guided ablations, with a median follow-up of 269 days (IQR 147). Of 93 suspicious foci, 62 (67%) grew (PMCD: +5.6% IQR: 5.8), 13 (14%) remained unchanged (PMCD: \u22120.1% IQR: 0.6), and 18 (19%) regressed (PMCD: \u22123.9% IQR: 4.2). Features [+iT2], [+ENH], and [+NOD] were associated with PMCDs of +5.2% IQR: 6.0, +3.4% IQR: 6.0, and +3.4% IQR: 6.5, respectively, compared to \u22121.5% IQR: 4.7 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), \u22120.5% IQR: 0.8 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), and +0.4% IQR: 7.5 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0056) for their respective negative counterparts. Sensitivity, specificity, and accuracy for distinguishing growth were [+iT2]: 0.95, 0.71, 0.87, [+ENH]: 1.00, 0.32, 0.77, and [+NOD]: 0.84, 0.42, 0.70. Combining [+iT2\u2009+\u2009NOD\u2009+\u2009ENH] yielded PMCD\u2009+5.9% IQR: 6.2 and the best performance for distinguishing growth (sensitivity 0.81, specificity 0.94, accuracy 0.85).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>MRI features reliably predict the growth of residual or recurrent DTs post-ablation, with [+iT2] being the most accurate. Adding nodular enhancement to [+iT2] improved specificity without sacrificing accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Post-ablation imaging of desmoids is challenging due to tumor heterogeneity and treatment-related inflammation. This study evaluates MRI features for assessing future tumor growth.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Foci of intermediate T2 signal post-ablation predicted desmoid growth with high sensitivity (0.95), while T2 signal, nodularity, and enhancement combined offer high specificity (0.94).<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Intermediate T2 signal predicts desmoid tumor growth post-ablation with high sensitivity and accuracy but moderate specificity. Combining nodularity and enhancement improves specificity and predictive value, helping clinicians in managing desmoid tumor patients post-ablation.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-024-11319-w","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:41:26Z","timestamp":1737459686000},"page":"4161-4170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-4458","authenticated-orcid":false,"given":"Daniel M.","family":"D\u00fcx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Chodakiewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul R.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Ghanouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Brunsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"11319_CR1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1054\/bjoc.1999.1007","volume":"82","author":"SB Middleton","year":"2000","unstructured":"Middleton SB, Frayling IM, Phillips RKS (2000) Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer 82:827\u2013832. https:\/\/doi.org\/10.1054\/bjoc.1999.1007","journal-title":"Br J Cancer"},{"key":"11319_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00019606-199704000-00005","volume":"6","author":"BA Alman","year":"1997","unstructured":"Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ (1997) Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol 6:98\u2013101. https:\/\/doi.org\/10.1097\/00019606-199704000-00005","journal-title":"Diagn Mol Pathol"},{"key":"11319_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0046-8177(96)90221-x","volume":"27","author":"M Li","year":"1996","unstructured":"Li M, Cordon-Cardo C, Gerald WL, Rosai J (1996) Desmoid fibromatosis is a clonal process. Hum Pathol 27:939\u2013943. https:\/\/doi.org\/10.1016\/s0046-8177(96)90221-x","journal-title":"Hum Pathol"},{"key":"11319_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CCO.0000000000000854","volume":"34","author":"R Mikhael","year":"2022","unstructured":"Mikhael R, Smith M, Tzanis D, Watson S, Miah AB, Bonvalot S (2022) Desmoid tumors: who, when and how to treat? Curr Opin Oncol 34:335\u2013341. https:\/\/doi.org\/10.1097\/CCO.0000000000000854","journal-title":"Curr Opin Oncol"},{"key":"11319_CR5","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.ctarc.2022.100562","volume":"31","author":"MY Zhou","year":"2022","unstructured":"Zhou MY, Bui NQ, Charville GW, Ghanouni P, Ganjoo KN (2022) Current management and recent progress in desmoid tumors. Cancer Treat Res 31:100562. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100562","journal-title":"Cancer Treat Res"},{"key":"11319_CR6","doi-asserted-by":"publisher","unstructured":"Kurtz JE, Buy X, Sauleau EA et al (2019) CRYODESMO-O1: a French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts). 30, v683. https:\/\/doi.org\/10.1093\/annonc\/mdz283.","DOI":"10.1093\/annonc\/mdz283"},{"key":"11319_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s00330-016-4376-5","volume":"27","author":"P Ghanouni","year":"2017","unstructured":"Ghanouni P, Dobrotwir A, Bazzocchi A et al (2017) Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol 27:732\u2013740. https:\/\/doi.org\/10.1007\/s00330-016-4376-5","journal-title":"Eur Radiol"},{"key":"11319_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00330-023-10073-9","volume":"34","author":"DM D\u00fcx","year":"2023","unstructured":"D\u00fcx DM, Baal JD, Bitton R, Chen J et al (2023) MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients. Eur Radiol 34:1137\u20131145. https:\/\/doi.org\/10.1007\/s00330-023-10073-9","journal-title":"Eur Radiol"},{"key":"11319_CR9","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.6004\/jnccn.2020.0058","volume":"18","author":"M von Mehren","year":"2020","unstructured":"von Mehren M, Kane JM, Bui MM et al (2020) NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1 (2021). J Natl Compr Canc Netw 18:1604\u20131612. https:\/\/doi.org\/10.6004\/jnccn.2020.0058","journal-title":"J Natl Compr Canc Netw"},{"key":"11319_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2214\/AJR.19.22635","volume":"215","author":"A Cromb\u00e9","year":"2020","unstructured":"Cromb\u00e9 A, Kind M, Ray-Coquard I et al (2020) Progressive desmoid tumor: radiomics compared with conventional response criteria for predicting progression during systemic therapy-a multicenter study by the French Sarcoma Group. AJR Am J Roentgenol 215:1539\u20131548. https:\/\/doi.org\/10.2214\/AJR.19.22635","journal-title":"AJR Am J Roentgenol"},{"key":"11319_CR11","doi-asserted-by":"publisher","first-page":"e210016","DOI":"10.1148\/rycan.2021210016","volume":"3","author":"TK Subhawong","year":"2021","unstructured":"Subhawong TK, Feister K, Sweet K et al (2021) MRI volumetrics and image texture analysis in assessing systemic treatment response in extra-abdominal desmoid fibromatosis. Radiol Imaging Cancer 3:e210016. https:\/\/doi.org\/10.1148\/rycan.2021210016","journal-title":"Radiol Imaging Cancer"},{"key":"11319_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00256-016-2439-y","volume":"45","author":"PJ Sheth","year":"2016","unstructured":"Sheth PJ, Del Moral S, Wilky BA et al (2016) Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol 45:1365\u20131373. https:\/\/doi.org\/10.1007\/s00256-016-2439-y","journal-title":"Skeletal Radiol"},{"key":"11319_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-018-0100-3","volume":"8","author":"M Libertini","year":"2018","unstructured":"Libertini M, Mitra I, van der Graaf WTA et al (2018) Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. Clin Sarcoma Res 8:13. https:\/\/doi.org\/10.1186\/s13569-018-0100-3","journal-title":"Clin Sarcoma Res"},{"key":"11319_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00330-019-06404-4","volume":"30","author":"PA Gondim Teixeira","year":"2020","unstructured":"Gondim Teixeira PA, Biouichi H, Abou Arab W et al (2020) Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. Eur Radiol 30:895\u2013902. https:\/\/doi.org\/10.1007\/s00330-019-06404-4","journal-title":"Eur Radiol"},{"key":"11319_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/SLA.0000000000003073","volume":"271","author":"MR Cassidy","year":"2020","unstructured":"Cassidy MR, Lefkowitz RA, Long N et al (2020) Association of MRI T2 signal intensity with desmoid tumor progression during active observation: a retrospective cohort study. Ann Surg 271:748\u2013755. https:\/\/doi.org\/10.1097\/SLA.0000000000003073","journal-title":"Ann Surg"},{"key":"11319_CR16","doi-asserted-by":"publisher","first-page":"615986","DOI":"10.3389\/fonc.2021.615986","volume":"11","author":"HC Zhu","year":"2021","unstructured":"Zhu HC, Xu SX, Li XT, Guan Z, Li S, Sun YS (2021) MRI T1 contrast-enhanced signal intensity is a prognostic indicator of imatinib therapy in desmoid-type fibromatosis. Front Oncol 11:615986. https:\/\/doi.org\/10.3389\/fonc.2021.615986","journal-title":"Front Oncol"},{"key":"11319_CR17","doi-asserted-by":"publisher","first-page":"20150308","DOI":"10.1259\/bjr.20150308","volume":"89","author":"F Kamali","year":"2016","unstructured":"Kamali F, Wang WL, Guadagnolo BA et al (2016) MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol 89:20150308. https:\/\/doi.org\/10.1259\/bjr.20150308","journal-title":"Br J Radiol"},{"key":"11319_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2214\/AJR.07.2334","volume":"189","author":"MB McCarville","year":"2007","unstructured":"McCarville MB, Hoffer FA, Adelman CS, Khoury JD, Li C, Skapek SX (2007) MRI and biologic behavior of desmoid tumors in children. AJR Am J Roentgenol 189:633\u2013640. https:\/\/doi.org\/10.2214\/AJR.07.2334","journal-title":"AJR Am J Roentgenol"},{"key":"11319_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ejrnm.2016.01.007","volume":"47","author":"BE Mahmoud","year":"2016","unstructured":"Mahmoud BE, Elkholy SF, Nabeel MM et al (2016) Role of MRI in the assessment of treatment response after radiofrequency and microwave ablation therapy for hepatocellular carcinoma. Egypt J Radiol Nucl Med 47:377\u2013385. https:\/\/doi.org\/10.1016\/j.ejrnm.2016.01.007","journal-title":"Egypt J Radiol Nucl Med"},{"key":"11319_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13244-020-00908-0","volume":"11","author":"F Rosa","year":"2020","unstructured":"Rosa F, Martinetti C, Piscopo F et al (2020) Multimodality imaging features of desmoid tumors: a head-to-toe spectrum. Insights Imaging 11:103. https:\/\/doi.org\/10.1186\/s13244-020-00908-0","journal-title":"Insights Imaging"},{"key":"11319_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1148\/rg.2016150153","volume":"36","author":"M Braschi-Amirfarzan","year":"2016","unstructured":"Braschi-Amirfarzan M, Keraliya AR, Krajewski KM et al (2016) Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics 36:767\u2013782. https:\/\/doi.org\/10.1148\/rg.2016150153","journal-title":"Radiographics"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11319-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:41:50Z","timestamp":1749814910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11319-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["11319"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11319-w","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantors of this publication are Ryan Brunsing, MD, PhD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: P.G.: Funding from INSIGHTEC. Advisory board for SonALAsense, Profound, and INSIGHTEC. Shareholder in SonALAsense. Consulted for HistoSonics, SONIRE, and Turing Medical. R.B.: Funding from GE Healthcare. The other co-authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) or their legally authorized representatives in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have been previously reported in Ghanouni P, et al [\n                      \n                      ]. D\u00fcx DM, Baal JD, Bitton R, Chen J, Brunsing RL, Sheth VR, Rosenberg J, Kim K, Ozhinsky E, Avedian R, Ganjoo K, Bucknor M, Dobrotwir A, Ghanouni P. (2024) MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients. Eur Radiol.\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}